When completed during the first half of 2017, the plant will be compliant with the Global Food Safety Initiative (GFSI) and Good Manufacturing Practices (GMP) standards.
“The Nantong plant offers customers a world-class facility that is fully integrated from beta picolines to niacinamide production, making Vertellus one of the world’s leading producers serving the vitamin B3 market segment,” said general manager of agriculture and nutrition Bernie Szalkowski.
The Nantong site began producing niacinamide in 2014 as the company sought to reduce logistics challenges and better serve Asian markets.
“The most recent investments at Nantong reflect Vertellus’ ongoing commitment to investing in facility improvements that serve vitamin B3 markets around the globe,” the company, which is headquartered in Indiana, added.